DOCSLIB.ORG

Breast Health

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Breast Health Breast Health Topic Index Female Sexual Function Index (FSFI)© Scoring; 0412 General Pain Assessment; 0413 General Education General Pain: Daily Self-Assessment; 0414 Antiperspirants and Breast Cancer; 0101 I’ve Found a Lump: Preparing for Physician’s Exam; Bra Fitting; 0102 0415 Breast Cancer Facts; 0103 Lymphedema Assessment; 0416 Breast Cancer Misconceptions and Facts; 0104 Male Breast Health Assessment; 0417 Breast Cancer Statistics; 0105 Mood Assessment: Post-Diagnosis; 0418 Breast Self-Exam; 0106 Mood Assessment: Post-Treatment; 0419 Caffeine Connection; 0107 Patient Support Needs Assessment; 0420 Frequently Asked Questions About the Breasts; 0108 Quality of Life Assessment; 0421 Range of Motion Assessment; 0422 Breast Anatomy Graphics Resource Needs Assessment; 0423 Breast Anatomy; 0201 Treatment Side Effects Calendar Record; 0424 Breast Diagram; 0202 Vital Signs Record; 0425 Female Breast and Breast Diagram; 0203 Female Breast Diagram; 0204 Breast Imaging Procedures Stages of Nodularity; 0205 Additional Mammography Views: Spot Compression and Magnification; 0501 Mammography Forms and Letters Breast-Specific Gamma Imaging (BSGI); 0502 Abnormal Mammogram: Biopsy Recommended; Calcifications - Microcalcifications; 0503 0301 Compression During Mammography; 0504 Abnormal Mammogram: Follow-Up Self Referral; Digital Mammography; 0505 0302 Galactography; 0506 Abnormal Mammogram: Immediate Follow-Up; 0303 Implants and Mammography; 0507 Diagnostic Mammogram: Normal Results; 0304 Magnetic Resonance Imaging (MRI) of the Breast; Mammography Consent Form; 0305 0508 Mammography Scheduling Questionnaire; 0306 Mammography Exam: Patient Overview; 0509 Requesting Your Mammography Film; 0307 Mammography Report From Radiologist; 0510 Screening Mammography: Results; 0308 Mammography Report Terminology; 0511 Methylene Blue Dye Localization; 0512 Assessment Tools Obtaining the Optimal Mammogram; 0513 Adjusting to Loss Assessment; 0401 Radiation Exposure Concerns; 0514 Anxiety Assessment; 0402 Tomosynthesis; 0515 Biopsy: Pre/Post Assessment; 0403 Blood Products Transfusion Assessment; 0404 Biopsy Procedures Breast Abnormality Patient Referral; 0405 Biopsy Risks; 0601 Breast Pain Assessment; 0406 Biopsy Types: Overview; 0602 Breast Patient: Clinical Referral; 0407 Breast Biopsy: Patient Instructions; 0603 Clinical Breast Assessment; 0408 Core Needle Biopsy; 0604 Decision-Making and Support Styles Assessment; EnCapsule Biopsy; 0605 0409 Excisional Biopsy; 0606 Extravasation Assessment; 0410 Fine Needle Aspiration; 0607 Female Sexual Function Index (FSFI)©; 0411 Fine Needle Aspiration (FNA) of a Cyst; 0608 © 2017 page 1 of 6 Incisional Biopsy; 0609 Breast Cancer Types TM Intact Biopsy; 0610 Apocrine Carcinoma; 0901 ® Large Core Biopsy — ABBI ; 0611 Cancer During Pregnancy: Most Frequently Asked Magnetic Resonance Breast Imaging (MRI): Breast Questions; 0902 Biopsy; 0612 Carcinoma In Situ: Comedo Pattern; 0903 Magnetic Resonance Breast Imaging (MRI): Needle Ductal Carcinoma In Situ; 0905 Localization; 0613 Ductal Carcinoma In Situ: Surgical Management; ® Mammotome Breast Biopsy; 0614 0906 Needle Localization: Breast Abnormality; 0615 Inflammatory Carcinoma; 0909 Needle Localization: Patient Instructions; 0616 Invasive (Infiltrating) Ductal Carcinoma; 0907 Skin Punch Biopsy; 0619 Invasive (Infiltrating) Lobular Carcinoma; 0908 Stereotactic Breast Biopsy; 0617 Lobular Carcinoma In Situ; 0910 Ultrasound Guided Breast Biopsy; 0618 Lymphoma of the Breast; 0911 Male Breast Cancer; 0912 Benign Breast Conditions Medullary Carcinoma; 0913 Accessory Breast Tissue; 0701 Mucinous Carcinoma; 0914 Atypical Hyperplasia; 0702 Paget Disease; 0915 Breast Abscess; 0703 Papillary Carcinoma; 0916 Breast Cellulitis; 0704 Phyllodes Tumor — Cystosarcoma; 0904 Breast Cysts; 0705 Tubular Carcinoma; 0917 Breast Pain; 0706 Dense Breasts; 0723 High Risk and Genetic Testing Duct Ectasia - Periductal Mastitis; 0707 BRCA Genetic Testing; 1001 Fat Necrosis Tumor; 0708 BRCA Genetic Testing: Negative Result; 1002 Fibroadenoma; 0709 BRCA Genetic Testing: Positive Result; 1003 Fibrocystic Changes; 0710 BRCA Genetic Testing: Uncertain Result; 1004 Galactocele; 0711 High Risk Recommended Reading List; 1005 Gynecomastia - Male; 0712 High Risk: Lifestyle Modifications; 1006 Hamartoma of the Breast; 0722 I’m High Risk: What Do I Do?; 1007 Itching Breasts; 0713 Lipomas; 0714 Surgery Mastitis; 0715 Breast Cancer Surgery Preparation; 1101 Mondor’s Syndrome; 0716 Breast Cancer Surgery: Patient Instructions; 1102 Nipple Discharge; 0717 Breast Self-Exam After Lumpectomy; 1135 Papilloma; 0718 Breast Self-Exam After Mastectomy; 1130 Radial Scar; 0719 Chemotherapy Central Line: Central Intravenous Sclerosing Adenosis; 0720 Port Surgery; 1103 Shingles (Herpes Zoster); 0721 Chemotherapy Central Line: Central Venous Catheter Surgery; 1104 Breast Cancer Characteristics Drain Bulb Record; 1105 Breast Cancer Growth Rate: How Long Has It Been Drains: Care and Instructions; 1106 There?; 0801 Exercise and Care of the Surgical Arm; 1131 Cancer Growth Rate; 0802 Hematoma; 1107 Cancer Progression Process; 0803 Hemorrhage After Breast Surgery; 1108 Estrogen and Progesterone Receptor Status; 0804 How Physicians Make Surgical Decisions; 1109 Grading of Invasive Breast Cancer; 0805 Informed Consent; 1110 Pathology Report; 0806 Lumpectomy; 1111 Stages of Breast Cancer; 0807 Lumpectomy: Discharge Instructions; 1112 Staging of Breast Cancer: Patient Explanation; 0808 Lumpectomy/Mastectomy Comparison; 1113 Tumor Markers; 0809 Lymphatic System: Understanding Its Role; 1114 What Is Breast Cancer?; 0810 Male Gynecomastia: Surgical Correction; 1115 © 2017 page 2 of 6 Mastectomy; 1116 Reconstructive Surgery: Criteria and Risk Factors; Mastectomy: Discharge Instructions; 1117 1218 Medications That Increase Bleeding; 1132 Reconstructive Surgery: Patient Instructions; 1219 Nipple-Sparing Mastectomy; 1118 Recovery After Breast Reconstruction; 1220 Peripherally Inserted Central Catheter (PICC Line); SGAP (Superior Gluteal Artery Perforator) Breast 1133 Reconstruction; 1221 Sentinel Lymph Node Mapping: Why?; 1119 TAP (Thoracodorsal Artery Perforator) Breast Sentinel Lymph Node Surgery; 1120 Reconstruction; 1222 Seroma; 1121 TRAM Free Flap Breast Reconstruction; 1226 Skin-Sparing Mastectomy; 1122 TRAM Muscle-Sparing Free Flap Breast Reconstruction; 1227 Surgical Decision: Patient Self-Assessment; 1123 TRAM Pedicle Flap Breast Reconstruction; 1223 Surgical Incision Care; 1124 TUG (Transverse Upper Gracilis) Breast Surgical Incision: Infection; 1125 Reconstruction; 1228 Tissue Necrosis: Debridement; 1126 What Every Patient Needs to Know About Breast Vascular Access Catheter Dressing Change; 1127 Implants; 1225 Venipunctures/Blood Pressure Checks: LEFT ARM; 1128 Treatments Venipunctures/Blood Pressure Checks: RIGHT ARM; Breast Brachytherapy: Mammosite®; 1301 1129 Breast Brachytherapy: Accelerated Partial Breast What Do I Do About My Other Breast?; 1134 Irradiation (APBI); 1302 Breast Cancer Index (BCI); 1327 Reconstruction Cancer Clinical Trials; 1303 Abdominal Autologous Reconstruction: Flap Chemosensitivity/Chemoresistance Testing; 1305 Composition and Blood Supply; 1230 Chemotherapy Drugs and Schedules; 1306 Autologous Reconstruction; 1201 Chemotherapy or Hormonal Therapy: Why Do I Breast Augmentation With Implants; 1231 Need It?; 1307 Breast Implants; 1202 Chemotherapy: Evaluating Cancer’s Response; 1308 Breast Implants: What Patients Need to Know; 1224 Chemotherapy: How Can We Tell If It’s Working?; Breast Reconstruction Options; 1203 1309 Breast Reconstruction Terms; 1233 Chemotherapy: How It Works; 1310 Breast Reduction; 1232 Chemotherapy: How Long Is Treatment Given?; Capsular Contracture From Breast Implants; 1224 1311 DIEP (Deep Inferior Epigastric Perforator) Breast Chemotherapy: Patient Infusion Tips; 1312 Reconstruction; 1205 Chemotherapy: Patient Questions; 1313 Flap Necrosis After Breast Reconstruction; 1206 Chemotherapy: Regional Delivery Devices; 1314 Flap Revisions After Breast Reconstruction; 1207 Chemotherapy: Targeted Drugs; 1315 IGAP (Inferior Gluteal Artery Perforator) Breast Dose-Dense Chemotherapy; 1316 Reconstruction; 1210 Hormonal Therapy Overview; 1317 Immediate or Delayed Reconstruction Decision; Hormonal Therapy: Patient Questions; 1318 1208 Immune System During Chemotherapy; 1319 Implants With Acellular Dermal Matrix; 1209 MammaPrint®; 1328 Latissimus Dorsi (LD) Breast Reconstruction; 1211 Medical Oncologist and Your Treatment Plan; 1320 Mammoplasty — Breast Reduction; 1212 Neoadjuvant Chemotherapy; 1321 Mastopexy — Breast Cosmetic Surgery; 1213 Oncotype DXTM; 1322 Nipple and Areola Reconstruction; 1214 Radiation Oncologist and Radiation Therapy; 1323 Nipple and Areola Tattooing; 1215 Radiation Therapy Tattoos; 1326 PAP (Profunda Artery Perforator) Breast Reconstruction; 1229 Second Opinions; 1324 Reconstruction Flap Types; 1216 Thoracentesis; 1325 Reconstructive Surgery: Advantages and Disadvantages; 1217 © 2017 page 3 of 6 Treatment Side Effects Hyperventilation: Panic Attack; 1445 Abdominal Pain During Chemotherapy Treatment; Hypocalcemia: Decreased Blood Calcium Levels; 1401 1446 Allergic Reaction to Chemotherapy or Drugs; 1402 Hypokalemia: Decreased Blood Potassium Levels; Alopecia: Hair Loss; 1403 1447 Anemia: Low Hemoglobin; 1404 Hyponatremia: Decreased Sodium Levels; 1448 Anxiety: Recognition & Management During Indigestion: Dyspepsia; 1449 Treatment; 1405 Insomnia; 1450 Appetite Changes During Chemotherapy; 1406 Jaw Pain With Zometa; 1451 Appetite Stimulation; 1407 Leukopenia: Low White
Load more

Recommended publications
  • Evicore Breast Imaging Guidelines
    CLINICAL GUIDELINES Breast Imaging Guidelines Version 2.0 Effective September 1, 2021 eviCore healthcare Clinical Decision Support Tool Diagnostic Strategies: This tool addresses common symptoms and symptom complexes. Imaging requests for individuals with atypical symptoms or clinical presentations that are not specifically addressed will require physician review. Consultation with the referring physician, specialist and/or individual’s Primary Care Physician (PCP) may provide additional insight. CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five digit codes, nomenclature and other data are copyright 2017 American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values or related listings are included in the CPT® book. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein. © 2021 eviCore healthcare. All rights reserved. Breast Imaging Guidelines V2.0 Breast Imaging Guidelines Abbreviations for Breast Guidelines 3 BR-Preface1: General Considerations 5 BR-1: Breast Ultrasound 8 BR-2: MRI Breast 10 BR-3: Breast Reconstruction 12 BR-4: MRI Breast is NOT Indicated 13 BR-5: MRI Breast Indications 14 BR-6: Nipple Discharge/Galactorrhea 18 BR-7: Breast Pain (Mastodynia) 19 BR-8: Alternative Breast Imaging Approaches 20 BR-9: Suspected Breast Cancer in Males 22 BR-10: Breast Evaluation in Pregnant or Lactating Females 23 ______________________________________________________________________________________________________
    [Show full text]
  • Biopsy Needles and Drainage Catheters
    Needles & Accessories | Catheters & Accessories Dilation & Accessories Spinal & Accessories | Implantable & Accessories Product Catalog ISO 13485 & ISO 9001 Certified Company Rev. 01 - 2019/03 About ADRIA Srl. Adria is a worldwide leader in developing, manufacturing and marketing healthcare products. The main focus is on Radiology, Oncology, Urology, Gynecology and Surgery . Adria' s corporate headquarter is based in Italy, it is ISO Certified and products are CE . marked. Adria was incorporated more than 20 years ago in Bologna , where the corporate headquarter and production plant is located. Adria is leader in developing and manufacturing healthcare products and keeps the status to be one of the first companies aimed to develop single patient use biopsy needles and drainage catheters. Over the time, thanks to the experience of specialized doctors and engineers , Adria product range and quality have been progressively enhanced, involving and developing the spine treatment line. Nowadays Adria has a worldwide presence . Reference markets are France, Spain, Turkey and products are distributed in more than 50 countries, through a large and qualified network of dealers. Since far off the very beginning, many things have changed, but Adria' s philosophy and purpose have always remained unchanged: helping healthcare providers to fulfill their mission of caring for patients. Table of Contents Needles & Accessories …………………………………………….....…...3 Catheters & Accessories ……………………….………………..…...…...18 Dilation & Accessories ……………………………………………...…...25 Spinal & Accessories ……………………………………………...…...30 Implantables & Accessories……………………………………………...…...35 Needles & Accessories HYSTO SYSTEM Automatic Biopsy Instrument……………………….……….…….. 4 HYSTO SYSTEM II Automatic Biopsy Instrument…………………….……….……...5 SAMPLE MASTER Semi-Automatic Biopsy Instrument…………………………….. 6 HYSTO-ONE Automatic Reusable Biopsy Instrument & MDA Biopsy Needle ....... 7 HYSTO-TWO Automatic Reusable Biopsy Instrument & MDS Biopsy Needle…...
    [Show full text]
  • Evaluation of Nipple Discharge
    New 2016 American College of Radiology ACR Appropriateness Criteria® Evaluation of Nipple Discharge Variant 1: Physiologic nipple discharge. Female of any age. Initial imaging examination. Radiologic Procedure Rating Comments RRL* Mammography diagnostic 1 See references [2,4-7]. ☢☢ Digital breast tomosynthesis diagnostic 1 See references [2,4-7]. ☢☢ US breast 1 See references [2,4-7]. O MRI breast without and with IV contrast 1 See references [2,4-7]. O MRI breast without IV contrast 1 See references [2,4-7]. O FDG-PEM 1 See references [2,4-7]. ☢☢☢☢ Sestamibi MBI 1 See references [2,4-7]. ☢☢☢ Ductography 1 See references [2,4-7]. ☢☢ Image-guided core biopsy breast 1 See references [2,4-7]. Varies Image-guided fine needle aspiration breast 1 Varies *Relative Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate Radiation Level Variant 2: Pathologic nipple discharge. Male or female 40 years of age or older. Initial imaging examination. Radiologic Procedure Rating Comments RRL* See references [3,6,8,10,13,14,16,25- Mammography diagnostic 9 29,32,34,42-44,71-73]. ☢☢ See references [3,6,8,10,13,14,16,25- Digital breast tomosynthesis diagnostic 9 29,32,34,42-44,71-73]. ☢☢ US is usually complementary to mammography. It can be an alternative to mammography if the patient had a recent US breast 9 mammogram or is pregnant. See O references [3,5,10,12,13,16,25,30,31,45- 49]. MRI breast without and with IV contrast 1 See references [3,8,23,24,35,46,51-55].
    [Show full text]
  • Ultrasound, Elastography and MRI Mammography
    EAS Journal of Radiology and Imaging Technology Abbreviated Key Title: EAS J Radiol Imaging Technol ISSN 2663-1008 (Print) & ISSN: 2663-7340 (Online) Published By East African Scholars Publisher, Kenya Volume-1 | Issue-2 | Mar-Apr-2019 | Research Article Ultrasound, Elastography and MRI Mammography Correlation in Breast Pathologies (A Study of 50 Cases) Dr Hiral Parekh.1, Dr Lata Kumari.2, Dr Dharmesh Vasavada.3 1Professor, Department of Radiodiagnosis M P Shah Government Medical College Jamnagar, Gujarat, India 2Resident Doctor in Radiodiagnosis Department of Radiodiagnosis M P Shah Government Medical College Jamnagar, Gujarat, India 3Professor, Department of Surgery M P Shah Government Medical College Jamnagar, Gujarat, India *Corresponding Author Dr Dharmesh Vasavada Abstract: Introduction: The purpose of this study is to investigate the value of MRI in comparison to US and mammography in diagnosis of breast lesions. MRI is ideal for breast imaging due to its ability to depict excellent soft tissue contrast. Methods: This study of 50 cases was conducted in the department of Radiodiagnosis, Guru Gobinsingh Government Hospital, M P Shah Government Medical College, Jamnagar, Gujarat, India. All 50 cases having or suspected to have breast lesions were chosen at random among the indoor and outdoor patients referred to the Department of Radiodiagnosis for imaging. Discussion: In the present study the results of sonoelastography were compared with MRI. The malignant masses were the commonest and the mean age of patients with malignant masses in our study was 45 years, which is in consistent with Park‟s statement that the mean age of breast cancer occurrence is about 42 years in India3.
    [Show full text]
  • Diagnostic Accuracy of Shear Wave Elastography for Prediction of Breast Malignancy in Patients with Pathological Nipple Discharge
    Open Access Research BMJ Open: first published as 10.1136/bmjopen-2015-008848 on 22 January 2016. Downloaded from Diagnostic accuracy of shear wave elastography for prediction of breast malignancy in patients with pathological nipple discharge Xiaobo Guo,1 Ying Liu,1 Wanhu Li2 To cite: Guo X, Liu Y, Li W. ABSTRACT Strengths and limitations of this study Diagnostic accuracy of shear Objectives: Pathological nipple discharge (PND) may wave elastography for indicate malignant breast lesions. As the role of shear ▪ prediction of breast Diagnostic accuracy of shear wave elastography wave elastography (SWE) in predicting these malignant malignancy in patients with (SWE) for detecting malignancy of patients with pathological nipple discharge. lesions has not yet been evaluated, we aim to evaluate PND has rarely been studied. BMJ Open 2016;6:e008848. the diagnostic value of SWE for this condition. ▪ For the first time, this study tested diagnostic doi:10.1136/bmjopen-2015- Design: Prospective diagnostic accuracy study accuracy of a synthesised measurement of quali- 008848 comparing a combination of qualitative and quantitative tative and quantitative measures of SWE for measurements of SWE (index test) to a ductoscopy detecting malignancy in patients with PND. ▸ Prepublication history for and microdochectomy for histological diagnosis ▪ Limitations include the fact that the weight of this paper is available online. (reference test). each measurement in the synthesised score was To view these files please Setting: Fuzhou General Hospital of Nanjing military assigned evenly and the surgeon was not visit the journal online command. blinded. (http://dx.doi.org/10.1136/ Participants: A total of 379 patients with PND were bmjopen-2015-008848).
    [Show full text]
  • Ijcem0007780.Pdf
    Int J Clin Exp Med 2015;8(6):8506-8515 www.ijcem.com /ISSN:1940-5901/IJCEM0007780 Original Article Ultrasound elastography and magnetic resonance examinations are effective for the accurate diagnosis of mammary duct ectasia Feixue Zhang1, Dexin Yu2, Mingming Guo3, Qing Wang2, Zhigang Yu3, Fei Zhou3, Meng Zhao2, Feng Xue2, Guangrui Shao4 1Department of Radiology, Division of Ultrasound, The Second Hospital of Shandong University, Jinan City, Shan- dong Province, P.R. China; 2Department of Radiology, Qilu Hospital, Shandong University, Jinan City, Shandong Province, P.R. China; 3Department of Breast Surgery, The Second Hospital of Shandong University, Jinan City, Shandong Province, P.R. China; 4Department of Radiology, The Second Hospital of Shandong University, Jinan City, Shandong Province, P.R. China Received March 10, 2015; Accepted May 28, 2015; Epub June 15, 2015; Published June 30, 2015 Abstract: Objectives: This study is to investigate the values of multiple quantitative evaluation parameters in the diagnosis of mammary duct ectasia (MDE), using real-time ultrasound elastography (UE) and magnetic resonance imaging (MRI). Methods: This retrospective study was performed on 15 patients (16 lesions) with MDE. Ultrasound examination was performed with the LOGIQ E9 ultrasound instrument, with all lesions being examined by routine ultrasound and UE. MRI examination was performed with a Signa HD × 3.0T TWINSP MR System, including of plain- scan, diffusion-weighted imaging, dynamic contrast-enhanced MRI, and proton magnetic resonance spectroscopy. Imaging features, as well as semi-quantitative and quantitative parameters, were analyzed to determine their diag- nostic value for MDE. Results: According to the five-point scale in UE, twelve lesions belonged to 1-3 point scale, and four lesions were in 4-5 point scale, with an average of 2.93 ± 0.77.
    [Show full text]
  • Journal of Surgery Leong A, Et Al
    Journal of Surgery Leong A, et al. J Surg: JSUR-1154. Research Article DOI: 10.29011/2575-9760. 001154 Variations in Abnormal Nipple Discharge Management in Women- a Systematic Review and Meta-analysis Alison Leong, Alison Johnston, Michael Sugrue* Department of Breast Surgery, Breast Centre North West, Donegal Clinical Research Academy, Letterkenny University Hospital, Done- gal, Ireland *Corresponding author: Michael Sugrue, Department of Breast Surgery, Breast Centre North West, Donegal Clinical Research Academy, Letterkenny University Hospital, Donegal, Ireland. Tel: +353749188823; Fax: +353749188816; Email: michael.sugrue@ hse.ie Citation: Leong A, Johnston A, Sugrue M (2018) Variations in Abnormal Nipple Discharge Management in Women- a Systematic Review and Meta-analysis. J Surg: JSUR-1154. DOI: 10.29011/2575-9760. 001154 Received Date: 13 July, 2018; Accepted Date: 19 July, 2018; Published Date: 26 July, 2018 Abstract Nipple discharge accounts for 5% of referrals to breast units; breast cancer in image negative nipple discharge patients varies from 0 to 21%. This systematic review and meta-analysis determined variability in breast cancer rates in nipple discharge patients, diagnostic accuracy of modalities and surgery rates. An ethically approved meta-analysis was conducted using data- bases PubMed, EMBASE, and Cochrane Library from January 2000 to July 2015. For the breast cancer rates’ review, studies were excluded if no clinical follow-up data was available. For the diagnostic accuracy meta-analysis, studies were excluded if there was no reference standard, or the number of true and false positives and negatives were not known. Pooled sensitivities were determined using Mantel-Haenszel method. For the surgery rates’ review, only studies with consecutive nipple discharge patients were included.
    [Show full text]
  • The Automated Breast Volume Scanner (ABVS): Initial Experiences in Lesion Detection Compared with Conventional Handheld B-Mode Ultrasound: a Pilot Study of 50 Cases
    International Journal of Women’s Health Dovepress open access to scientific and medical research Open Access Full Text Article ORIGINAL RESEARCH The Automated Breast Volume Scanner (ABVS): initial experiences in lesion detection compared with conventional handheld B-mode ultrasound: a pilot study of 50 cases Sebastian Wojcinski1 Abstract: The idea of an automated whole breast ultrasound was developed three decades ago. Andre Farrokh1 We present our initial experiences with the latest technical advance in this technique, the automated 2 Ursula Hille breast volume scanner (ABVS) ACUSON S2000TM. Volume data sets were collected from 50 3 Jakub Wiskirchen patients and a database containing 23 women with no detectable lesions in conventional ultrasound Samuel Gyapong1 (BI-RADS®-US 1), 13 women with clearly benign lesions (BI-RADS®-US 2), and 14 women with Amr A Soliman1,4 known breast cancer (BI-RADS®-US 5) was created. An independent examiner evaluated the ABVS Friedrich Degenhardt1 data on a separate workstation without any prior knowledge of the patients’ histories. The diagnostic Peter Hillemanns2 accuracy for the experimental ABVS was 66.0% (95% confidence interval [CI]: 52.9–79.1). The 1 Department of OB/GYN, Franziskus independent examiner detected all breast cancers in the volume data resulting in a calculated sensi- Hospital, Bielefeld, Germany; 2Department of OB/GYN, Hannover Medical School, tivity of 100% in the described setting (95% CI: 73.2%–100%). After the ABVS examination, there 3 Hannover, Germany; Department of were a high number of requests for second-look ultrasounds in 47% (95% CI: 30.9–63.5) of the Radiology, Franziskus Hospital, Bielefeld, Germany; 4Department of OB/GYN, Faculty healthy women (with either a clearly benign lesion or no breast lesions at all in conventional handheld of Medicine, University of Alexandria, ultrasound).
    [Show full text]
  • DBT-Galactography: a Promising Tool for Improving the Diagnostic Workup
    Moschetta et al. European Radiology Experimental (2020) 4:40 European Radiology https://doi.org/10.1186/s41747-020-00170-5 Experimental ORIGINAL ARTICLE Open Access DBT-galactography: a promising tool for improving the diagnostic workup of nipple discharge Marco Moschetta1*, Vincenzo De Ruvo1, Angelica Drago2, Nicoletta Troiano2, Simona Paolicelli2, Giuseppe Rubini2, Amato Antonio Stabile Ianora2 and Michele Telegrafo1 Abstract Background: Our aim was to compare the diagnostic performance of digital breast tomosynthesis (DBT)- galactography with that of full-field digital (FFD)-galactography for detecting intraductal breast lesions using an intra-individual design. Methods: Forty-nine consecutive patients with spontaneous, unilateral, single-pore nipple discharge and inconclusive FFD mammography and ultrasonography underwent galactography with a “COMBO” technique combining FFD- and DBT-galactography acquisitions. Examinations were independently analysed by two breast radiologists with 10-year experience. Sensitivity, specificity, and accuracy for both FFD- and DBT-galactography were calculated having histological examinations of surgical specimens as a reference standard. Data were presented as percentages with their 95% confidence intervals (CI). McNemar test was used. Interobserver agreement was assessed by using Cohen κ test for both techniques. Results: Sensitivity was 41/43 (95%, 95% CI 84.2–99.4) for DBT-galactography and 33/43 (77%, 95% CI 61.4–88.2) for FFD-galactography (p = 0.008), specificity 6/6 (100%, 95% CI 54.1–100.0) for both imaging tools, accuracy 47/49 (96%, 95% CI 86.0–99.5) and 39/49 (80%, 95% CI 65.7–89.8) (p = 0.038), respectively. The inter-observer agreement was 0.86 for DBT-galactography and 0.78 for FFD-galactography.
    [Show full text]
  • Evicore Breast Imaging
    CLINICAL GUIDELINES Breast Imaging Policy Version 1.0 Effective February 14, 2020 eviCore healthcare Clinical Decision Support Tool Diagnostic Strategies: This tool addresses common symptoms and symptom complexes. Imaging requests for individuals with atypical symptoms or clinical presentations that are not specifically addressed will require physician review. Consultation with the referring physician, specialist and/or individual’s Primary Care Physician (PCP) may provide additional insight. CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five digit codes, nomenclature and other data are copyright 2017 American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values or related listings are included in the CPT® book. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein. © 2019 eviCore healthcare. All rights reserved. Breast Imaging Guidelines V1.0 Breast Imaging Guidelines Abbreviations for Breast Guidelines 3 BI-RADS™ Categories Chart 5 BR-1: Breast Ultrasound 7 BR-2: MRI Breast 8 BR-3: Breast Reconstruction 10 BR-4: MRI Breast is NOT Indicated 11 BR-5: MRI Breast Indications 12 BR-6: Nipple Discharge/Galactorrhea 15 BR-7: Breast Pain (Mastodynia) 16 BR-8: Alternative Breast Imaging Approaches 17 BR-9: Suspected Breast Cancer in Males 18 ______________________________________________________________________________________________________
    [Show full text]
  • CAR Breast Imaging and Intervention Guideline
    CAR PRACTICE GUIDELINES AND TECHNICAL STANDARDS FOR BREAST IMAGING AND INTERVENTION APPROVED ON SEPTEMBER 29, 2012 CHAIR, SHIELA APPAVOO, MD; ANN ALDIS, MD; PETRINA CAUSER, MD; PAVEL CRYSTAL, MD; BENOÎT MESUROLLE, MD; YOLANDA MUNDT, MRT; NEETY PANU, MD; JEAN SEELY, MD; NANCY WADDEN, MD MODIFIED ON SEPTEMBER 17, 2016: CHAIR, SHIELA APPAVOO, MD; ANN ALDIS, MD; PETRINA CAUSER, MD; PAVEL CRYSTAL, MD; ANAT KORNECKI, MD; YOLANDA MUNDT, MRT; JEAN SEELY, MD; NANCY WADDEN, MD The practice guidelines of the Canadian Association of Radiologists (CAR) are not rules, but are guidelines that attempt to define principles of practice that should generally produce radiological care. The radiologist and medical physicist may modify an existing practice guideline as determined by the individual patient and available resources. Adherence to CAR practice guidelines will not assure a successful outcome in every situation. The practice guidelines should not be deemed inclusive of all proper methods of care or exclusive of other methods of care reasonably directed to obtaining the same results. The practice guidelines are not intended to establish a legal standard of care or conduct, and deviation from a practice guideline does not, in and of itself, indicate or imply that such medical practice is below an acceptable level of care. The ultimate judgment regarding the propriety of any specific procedure or course of conduct must be made by the physician and medical physicist in light of all circumstances presented by the individual situation. Approved on September
    [Show full text]
  • Recommendations for Medical Imaging Procedures
    Recommendations for medical imaging procedures Recommendation by the German Commission on Radiological Protection Adopted at the 300th SSK meeting on 27 June 2019 For many decades, diagnostic imaging has been an indispensable tool of ensure referral guidelines modern medicine to clarify diagnostic questions, thus allowing for the for medical imaging, taking planning of appropriate individual treatments. Some examination methods into account the radiation such as X-ray or nuclear medical diagnostics involve ionising radiation or doses, are available to the radioactive substances. In view of the radiological exposure involved in referrers. such procedures, physicians must consider carefully whether a different The Federal Environment diagnostic method with less or no radiation exposure, such as ultrasound Ministry, being responsible for radiological protection, has for many years or magnetic resonance procedures, might not be at least equally well advocated keeping the number of applications involving radiation suited for a specific patient. Therefore the Recommendations for medical exposure as low as possible. There is constant enhancement of imaging procedures address first of all physicians referring patients for diagnostic procedures and therefore these recommendations are further diagnostics. The goal is to avoid unnecessary radiation exposure reviewed and updated on a regular basis. while achieving the same level of diagnostic accuracy. I would like to thank the German Commission on Radiological Protection, the The recommendations list the most suitable imaging procedures for various medical associations involved and in particular the working group under various diagnostic questions. However, physicians must still provide in the chair of Professor Reinhard Loose for their work. each individual case the justifying indication for the selected examination method and document it.
    [Show full text]